Open Access

Evaluation of various blood biomarkers associated with the outcomes of patients with COVID‑19 treated in intensive care units

  • Authors:
    • Sidika Genc
    • Ali Taghizadehghalehjoughi
    • Muhammet E. Naldan
    • Oktay Gülcü
    • Cüneyt Caglayan
    • Marios Spanakis
    • Taxiarchis Konstantinos Nikolouzakis
    • Athanasios Alegakis
    • Anca Oana Docea
    • Andrei Ioan Drocas
    • Radu Mitrut
    • Eleftheria Hatzidaki
    • Demetrios A. Spandidos
    • Aristidis Tsatsakis
  • View Affiliations

  • Published online on: January 4, 2024     https://doi.org/10.3892/etm.2024.12371
  • Article Number: 82
  • Copyright: © Genc et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection and the resulting coronavirus disease 2019 (COVID‑19) represented a global public health crisis and the most significant pandemic in modern times. Transmission characteristics, and the lack of effective antiviral treatment protocol and protective vaccines, pushed healthcare systems, particularly intensive care units (ICUs), to their limits and led to extreme quarantine measures to control the pandemic. It was evident from an early stage that patient stratification approaches needed to be developed to better predict disease progression. In the present study, the predictive value of clinical and blood biomarkers for the outcomes of patients with COVID‑19 hospitalized in the ICU were investigated, taking age and sex into consideration. The present study analyzed blood samples from 3,050 patients with COVID‑19 hospitalized in the ICU. The analysis revealed that the levels of procalcitonin, N‑terminal pro‑B‑type natriuretic peptide, D‑dimer, ferritin, liver enzymes, C‑reactive protein and lactate dehydrogenase were increased and were associated with disease progression, resulting in a prolonged hospitalization period and severe COVID‑19 related complications. Additionally, significant age and sex disparities among these biomarkers were documented and discussed in specific cases. On the whole, the results of the present study suggest a potential association of the demographic characteristics and blood biomarkers with prolonged hospitalization in the ICU and the mortality of patients with COVID‑19.
View Figures
View References

Related Articles

Journal Cover

February-2024
Volume 27 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Genc S, Taghizadehghalehjoughi A, Naldan ME, Gülcü O, Caglayan C, Spanakis M, Nikolouzakis TK, Alegakis A, Docea AO, Drocas AI, Drocas AI, et al: Evaluation of various blood biomarkers associated with the outcomes of patients with COVID‑19 treated in intensive care units. Exp Ther Med 27: 82, 2024.
APA
Genc, S., Taghizadehghalehjoughi, A., Naldan, M.E., Gülcü, O., Caglayan, C., Spanakis, M. ... Tsatsakis, A. (2024). Evaluation of various blood biomarkers associated with the outcomes of patients with COVID‑19 treated in intensive care units. Experimental and Therapeutic Medicine, 27, 82. https://doi.org/10.3892/etm.2024.12371
MLA
Genc, S., Taghizadehghalehjoughi, A., Naldan, M. E., Gülcü, O., Caglayan, C., Spanakis, M., Nikolouzakis, T. K., Alegakis, A., Docea, A. O., Drocas, A. I., Mitrut, R., Hatzidaki, E., Spandidos, D. A., Tsatsakis, A."Evaluation of various blood biomarkers associated with the outcomes of patients with COVID‑19 treated in intensive care units". Experimental and Therapeutic Medicine 27.2 (2024): 82.
Chicago
Genc, S., Taghizadehghalehjoughi, A., Naldan, M. E., Gülcü, O., Caglayan, C., Spanakis, M., Nikolouzakis, T. K., Alegakis, A., Docea, A. O., Drocas, A. I., Mitrut, R., Hatzidaki, E., Spandidos, D. A., Tsatsakis, A."Evaluation of various blood biomarkers associated with the outcomes of patients with COVID‑19 treated in intensive care units". Experimental and Therapeutic Medicine 27, no. 2 (2024): 82. https://doi.org/10.3892/etm.2024.12371